Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session I

567 - STELLAR – Final updated results of a phase 2 trial of TTFields with chemotherapy for unresectable malignant pleural mesothelioma

Date

11 Apr 2019

Session

Mini Oral session I

Presenters

Giovanni Luca Ceresoli

Citation

Annals of Oncology (2019) 30 (suppl_2): ii72-ii73. 10.1093/annonc/mdz069

Authors

G.L. Ceresoli1, J.G. Aerts2, R. Dziadziuszko3, S. Cedres4, B. Hiddinga5, J.P. Van Meerbeeck6, M. Mencoboni7, D. Planchard8, A. Chella9, L. Crinò10, M.J. Krzakowski11, J. Madrzak3, R. Ramlau12, F. Grosso13

Author affiliations

  • 1 Humanitas Gavazzeni, 24125 - Bergamo/IT
  • 2 Erasmus University Medical Center, 3015 CE - Rotterdam/NL
  • 3 Medical University of Gdańsk, Gdańsk/PL
  • 4 Medical Oncology, Vall d'Hebron University Hospital, 8035 - Barcelona/ES
  • 5 University Hospital Groningen (UMCG), 9700 RB - Groningen/NL
  • 6 U.Z.A. University Hospital Antwerp, 2650 - Edegem/BE
  • 7 Ospedale Villa Scassi, 16149 - Genova/IT
  • 8 Institut Gustave Roussy, 94800 - Villejuif/FR
  • 9 Cisanello University hospital Pisa, 56124 - Pisa/IT
  • 10 Medical Oncology, Istituto Tumori della Romagna I.R.S.T., 47014 - Meldola/IT
  • 11 Department Of Lung & Thoracic Tumours, The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), 02-781 - Warsaw/PL
  • 12 Poznan University of Medical Sciences, Poznan/PL
  • 13 Ospedale di Alessandria, 15121 - Alessandria/IT
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 567

Background

Tumor Treating Fields (TTFields), an anti-mitotic, regional treatment approved for glioblastoma utilizes low intensity, alternating electric fields delivered non-invasively to the tumor using a portable medical device. In-vitro, human mesothelioma cells were highly susceptible to TTFields.

Methods

The trial accrued 80 patients with unresectable, previously untreated mesothelioma. Patients were treated with continuous 150 kHz TTFields (>18h/day) in combination with pemetrexed and cisplatin or carboplatin. Inclusion criteria included ECOG PS of 0-1 and pathologically proven mesothelioma. The primary endpoint was overall survival (OS). A visual analog scale was used to assess EOCG performance status and cancer-related pain assessed until disease progression. The sample size provided 80% power with two-sided alpha of 0.05 to detect an increase in median OS of 5.5 months compared to historical controls (Vogelzang, JCO 2003).

Results

All 80 patients had a minimum follow up of 12 months. Median age was 67 (range 27-78), 84% were male and 44% (35 patients) had an ECOG PS of 1. 66% (53 patients) had epithelioid histology, similar to the Vogelzang study. Median OS was 18.2 months (95% CI 12.1-25.8) versus 12.1 months in the historical control. Median OS for epithelioid patients was 21.2 months (95% CI 13.2-25.8). ECOG score was stable during the first year of follow up. Median time to deterioration in performance status was 13.1 months. Average score of pain was lower compared to baseline during the first 7 months of the treatment and was higher later on the study, with a median time to a clinical significant 33% increase in pain of 8.4 months. No device-related serious adverse events (AEs) were reported. Expected TTFields-related dermatitis was reported in 46% (37 patients). Four patients (5%) had grade 3 dermatitis.

Conclusions

The study met primary endpoint of significant extension of overall survival in previously untreated mesothelioma patients. TTFields was not associated with a decrease in performance status or an increase in pain for the duration of TTFields use. TTFields in combination with chemotherapy is efficacious in malignant pleural mesothelioma compared to historical data.

Clinical trial identification

NCT02397928.

Editorial acknowledgement

Legal entity responsible for the study

Novocure.

Funding

Novocure.

Disclosure

G.L. Ceresoli, F. Grosso: Travel funds: Novocure. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings